Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.

What Is The Role Of Preventative HIV Medicines?

Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".

In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.

HIV In Japan

Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.

Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.

What Are The Challenges In Implementation?

The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.

Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.

Better Healthcare Support

Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.

Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.

What Is The Way Ahead?

Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.

However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has introduced new measures to improve how the risks of suicidal thoughts and behaviors and persistent sexual dysfunction are communicated to people taking antidepressants.

Following a review involving patients and their families, the MHRA will introduce a boxed warning in patient information leaflets (PILs), a patient safety card, and an additional safety leaflet. The term “post-SSRI sexual dysfunction” (PSSD) will also be added to the leaflets for certain antidepressants.

“Patients need clear and accessible information about the benefits and risks of medicines so they can make informed decisions,” Dr. Alison Cave, MHRA chief safety officer, said.

She said the changes would support informed discussions among patients, caregivers, and healthcare professionals. Dr. Cave added that antidepressants can effectively treat depression when used appropriately and under clinical supervision. Patients should not stop taking these medicines without first consulting their healthcare professional.

What Are the New Antidepressant Warnings?

Also read: GLP-1 Drugs May Offer Mental Health Benefits, Reduce Schizophrenia Relapses: Lancet Study

Patient information leaflets will feature a boxed warning directing readers to information about suicidal thoughts and behaviors, making the guidance easier to find.

A patient safety card is expected to accompany medicine packaging, reinforcing key safety messages and explaining when and how to seek support.

For certain antidepressants, updated leaflets will include information on PSSD, highlighting the possibility that sexual dysfunction may persist after treatment ends.

The MHRA is also developing an additional safety leaflet with the wider healthcare system. Expected in 2027, it will explain the benefits and risks of antidepressant treatment to support informed decisions. It will be given to patients at their first appointment discussing antidepressants and to those already receiving treatment.

Concerns Over SSRI Safety Warnings

The MHRA has received four prevention of future deaths reports since 2020 concerning antidepressant prescribing and safety information. One followed the 2024 death by suicide of Thomas Kingston, husband of Lady Gabriella Kingston, at age 45.

An inquest heard that Kingston had been prescribed sertraline and later switched to citalopram after reporting that his medication was not helping. Both are selective serotonin reuptake inhibitors (SSRIs). He had also received the sleeping tablet zopiclone for sleep difficulties and had stopped taking his medication before his death.

Gloucestershire senior coroner Katy Skerrett questioned whether patients were adequately informed about the suicide risks associated with SSRIs. Kingston’s parents called for clearer communication of potential side effects to patients and their families.

Read More: AI Chatbots May Be Changing How Children Seek Emotional Support

What Should Healthcare Professionals Do?

The MHRA advises healthcare professionals to:

• Discuss the risk of suicidal thoughts and behaviors when starting antidepressants, changing doses, and during subsequent reviews.
• Explain that some antidepressants can cause sexual dysfunction that may continue after treatment stops.
• Follow relevant National Institute for Health and Care Excellence (NICE) guidance and monitor patients regularly after treatment begins.
• Provide the additional safety leaflet when it becomes available in 2027.
• Report suspected adverse reactions through the MHRA’s Yellow Card scheme.

What Should Patients Taking Antidepressants Know?

Patients experiencing new or worsening suicidal thoughts should seek urgent medical attention, particularly when starting treatment or changing their dose. In the UK, they can contact NHS 111, their local mental health crisis team, Samaritans on 116 123, or the SHOUT text service at 85258.

Anyone concerned about sexual dysfunction during or after antidepressant treatment should contact their healthcare professional.

The MHRA said these are not new risks associated with the medicines. Patients should read the information supplied with their medication and consult their healthcare professional before stopping treatment.

Lead poisoning is a widespread but preventable health threat that contributes to more than 3.5 million deaths globally each year and puts hundreds of millions of children at risk, the World Health Organization (WHO) said.

Marking International Lead Poisoning Prevention Week 2026, WHO urged countries to accelerate prevention efforts amid growing global momentum to tackle lead exposure.

Why Is Lead Dangerous for Children?

Also read: Lead Found In Everyday Vegetables - Reveals A Bengaluru Study

Children are particularly vulnerable to lead because their developing brains and nervous systems are highly susceptible to its toxic effects. Even low levels of exposure can cause irreversible harm, affecting learning, behavior and development.

“Lead poisoning should not be stealing children's potential in 2026,” said Bruce Gordon, Director a.i. of WHO’s Department of Environment, Climate Change, One Health and Migration.

“We know where many exposures come from and we know how to prevent them. Countries now need to move upstream, removing lead from products and environments before it reaches a child's bloodstream. WHO is working with governments and partners to help turn that evidence into action,” Gordon added.

How Does Lead Poisoning Occur?

There is no known safe level of lead exposure, WHO warned. Exposure can occur through paint, cookware, cosmetics, spices, informal recycling and industrial contamination, among other sources.

Lead affects multiple organs and can contribute to cardiovascular and kidney disease in adults. In children, exposure can cause lasting damage to brain function and development. Its effects may go undetected until significant harm has occurred.

Lead is distributed to the brain, liver, kidney and bones. It is stored in the teeth and bones, where it can accumulate over time. Human exposure is assessed through the measurement of lead in blood.

WHO Plans Global Action On Lead Exposure

Fewer than half of countries had confirmed legally binding controls on lead paint, according to WHO's latest published global assessment.

This year's International Lead Poisoning Prevention Week theme, “From Detection to Prevention,” highlights the need for stronger policies, better enforcement of safety standards and greater public awareness to eliminate lead hazards at their source.

WHO Member States have recognized lead exposure as a pressing public health concern and mandated the development of a Global Action Plan on Lead Mitigation, which will be presented to the World Health Assembly in 2027.

The WHO will also launch the PREVENT Technical Package on Lead Poisoning Prevention in 2027. It will provide practical guidance to help countries identify major exposure sources, prioritize interventions, strengthen regulations and track progress.

Last year, WHO joined partners in the Lead Poisoning Prevention Initiative to strengthen laboratory capacity for blood lead testing, supporting the monitoring and early detection of exposure.

The initiative will provide technical support and build laboratory capacity in Brazil, five states in India, Nepal and six sub-Saharan African countries: Ethiopia, Ghana, Malawi, Rwanda, South Africa and the United Republic of Tanzania.

WHO Calls for Stronger Prevention Measures

Preventing lead exposure can also reduce health care costs, improve educational outcomes and support healthier, more productive societies.

The WHO urged countries to move beyond detecting lead exposure and adopt comprehensive prevention strategies such as:

• Eliminating lead hazards from products and environments.
• Strengthening regulations and enforcement.
• Improving monitoring and surveillance of lead exposure.
• Strengthening capacity to manage lead poisoning cases.
• Raising public awareness about exposure sources and prevention.
• Promoting safer industrial practices and waste management.
• Prioritizing children and other vulnerable populations.

Scottish swimmer Archie Goodburn has welcomed the UK government’s plans to review progress in brain cancer research after years of campaigning for better treatment and greater investment in research.

Goodburn, 25, revealed in 2024 that he had been diagnosed with three inoperable brain tumors. In August, he broke down during an interview on BBC Breakfast as he spoke about the challenges faced by patients with brain cancer and their families.

He appealed to the government to invest more in research, urging it to “give us a chance to fight for our lives.” His plea led to a meeting with Prime Minister Andy Burnham.

The government has now announced a new national brain cancer clinical lead and a review of progress in brain cancer research, with the aim of helping patients access treatments sooner, the BBC reported.

Goodburn thanked the prime minister, saying all three of his requests had been “promised to some extent,” although the details still needed to be worked out.

Burnham described Goodburn as an “inspiration to us all” and said he was “delighted” to welcome him to Downing Street.

“He has spoken passionately about the need for change on brain cancer, and he's right: progress hasn't been good enough, here or anywhere else. Families facing this disease can't afford to wait,” Burnham said.

How Will the Brain Cancer Review Work?

Also read: 'Give Us a Chance to Fight': Archie Goodburn Makes Emotional Appeal For Better Brain Cancer Research; UK PM Responds

According to the BBC, the review will be led by Professor Anthony Chalmers, chair of clinical oncology at the University of Glasgow. It will assess progress in brain cancer research since 2018 and identify “what is still holding progress back.”

The review will be followed by a national cancer plan aimed at getting new treatments “out of the lab and to patients faster,” Downing Street said.

The prime minister has also asked the Medicines and Healthcare products Regulatory Agency (MHRA) to complete its review of regulations for medicines used to treat rare conditions sooner.

Goodburn has urged the regulator to finish the review within two years rather than three, bringing forward potential changes that could help patients access new treatments sooner.

Scotland Pledges Support for Brain Cancer Care

Read More: Saba Ali Khan Opens Up About Brain Tumour: Can It Go Unnoticed If You Walk, Talk And Work Normally?

Scottish First Minister John Swinney, who also recently met Goodburn, highlighted the Scottish government's commitment to supporting more clinical trials.

“We are proud to support national leadership for brain cancer through the Scottish Adult Neuro-Oncology Network,” Swinney said.

The network brings together clinicians, patients and voluntary sector representatives to improve care for people with brain cancer across Scotland.

“We will give careful consideration to any further role which Scotland could play to give people living with brain cancer a faster route from research to treatment,” he added.

Archie Goodburn's Brain Cancer Diagnosis

READ: Survival In Aggressive Brain Tumors Improves By Up To 50% in India, Say Doctors

The Edinburgh-born swimmer sought medical tests after experiencing numbness and seizures while training for the 2024 Olympic trials. He was diagnosed with three large oligodendrogliomas, a rare type of tumor that can affect the brain and spinal cord.

He underwent chemotherapy and radiotherapy, but surgery to remove the tumors was not possible.

Despite his diagnosis, Goodburn competed at the 2026 Commonwealth Games in Glasgow, reaching the final of the 50-meter breaststroke but narrowly missing out on a medal.

Charity Brain Tumour Research has described brain tumors as the cancer most likely to kill people under 40 in the UK.

“One of my dreams is that we see a future where brain cancer isn't the biggest killer of patients under 40,” Goodburn said during the Commonwealth Games.